Glenmark likely to out licence GRC 10693

2009 April 18

tags: Analysis-Reports, Glenmark, Latest News, share market of India

by Preeti

Pharma major Glenmark is likely to out licence GRC 10693, reports CNBC-TV18 quoting sources. The company is likely to receive upfront payment of up to $ 40 million.

Glenmark has completed Phase I trial of GRC 10693 in Europe. GRC 10693 is a pain relieving drug. Glen Saldanha speaking to CNBC-TV18 said that the company is in active conversation to out licence GRC 10693

Your Ad Here

No related posts.

Comments are closed for this entry.

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 India License

Vigilance Theme by Jestro

DISCLAIMER : Stock trading involves high risk and one can lose Substantial amount of money.The recommendations made herein Do not constitute an offer to sell or solicitation to buy any of the Securities mentioned. No representations can be made that recommendations contained herein will be profitable or they will Not result in losses. Readers using the information contained herein are solely responsible for their actions. The information is obtained from sources deemed to be reliable but is not guaranteed as to accuracy and completeness. The above recommendations are based on technical analysis only.

News about Indian Stock Markets

Glenmark likely to out licence GRC 10693

Recent Posts

Categories

Archives

Search

Authors

What I'm Doing...